iCOUGH: Accumulative Breath Cougher for Spinal Cord Injuries

Nahmias Yaakov, HUJI, School of Computer Science and Engineering, Bio-Engineering


Medical Devices, Drug Delivery, Respiratory System

Current development stage

Proof-of- Concept and a demonstration designed.

A prototype suitable for mass production may be produced within 12 months.


COVID-19 Application

95% of COVID-19 patient are “mild patient” and could be treated at home setting.

More than 97% present respiratory symptoms.

All hospitalization are cause by respiratory deterioration.

Today, remote monitoring of systemic parameters (saturation, heartbeat, body temperature) provide too late indication of respiratory deterioration.

iCough helps to manage the patient respiratory status by:

  • Direct measurements of respiratory functions
  • Smart algorithm to assist early detection of respiratory deteriorations.
  • Assist with airway clearance



Spinal cord injuries (SCI) impair the ability to breathe deeply and cough forcefully. As a result, SCI patients cannot clear the mucus produced in the airway system, which can lead to morbidity and mortality associated with respiratory infections and decreased quality of life.

Current solutions

Current solutions vary and include one of the possible techniques:

  • The utilization of professional physiotherapists who perform physical maneuvers that assists patients to cough.
  • Various expensive hospital coughers that are immobile and not adjusted for home usage and require the expertise and assistance of medical personnel.
  • Various mechanical inflation-exhalation devices that are fitted for home use, but currently can only be used with others' assistance.

Our Innovation

We deliver an efficient, convenient, cost-effective and accessible way to produce cough among SCI patient that can be operated solely by the patient.

The device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system.

In addition, we incorporate a venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient.


Unlike standard nebulizers and inhalers, our device actively delivers air or drug using large volume of pressurized air directly to the target site. As a result, it does not rely on distribution, the user’s breath or diffusion. Therefore, thr distribution either could go all the way to the alveoli itself, or directly to obstructed or blocked region.


SCI patients suffer from 38,000 complications per year due to impaired coughing. The average cost per patient reaches up to $66K.



Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME:
All projects by:Nahmias Yaakov (5)